Abstract
Diabetes is one of the most comprehensive metabolic disorders and is spread across the globe. The data from IDF Diabetes Atlas and National Diabetes Statistics mentions that the number of patients with diabetes is increasing at an exponential rate which is challenging the current therapeutics used for the management of diabetes. However, current therapies used for the treatment may provide symptomatic relief but lack in preventing the progression of the disease and thereby limiting the treatment of diabetes-associated complications. A thorough review and analysis were conducted using various databases including EMBASE, MEDLINE, and Google Scholar to extract the available information on challenges faced by current therapies which have triggered the development of novel molecules or drugs. From the analysis, it was analyzed that transforming growth factor βs (TGF-βs) have been shown to exhibit pleiotropic activity and are responsible for maintaining homeostasis and its overexpression is convoluted in the pathogenesis of various disorders. Therefore, develo** drugs that block TGF-β signaling may provide therapeutic benefits. This extensive review concluded that drugs targeting TGF-β signaling pathway and its subsequent blockade have shown promising results and hold the potential to become drugs of choice in the management of diabetes and associated complications.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data availability
Not applicable.
References
Ai J, Nie J, He J, Guo Q, Li M, Lei Y, Liu Y, Zhou Z, Zhu F, Liang M, Cheng Y (2015) GQ5 hinders renal fibrosis in obstructive nephropathy by selectively inhibiting TGF-β–induced Smad3 phosphorylation. J Am Soc Nephrol 26(8):1827–1838. https://doi.org/10.1681/ASN.2014040363
Akhurst RJ (2017) Targeting TGF-β signaling for therapeutic gain. Cold Spring Harb Perspect Biol 9(10):a022301. https://doi.org/10.1101/cshperspect.a022301
Alsulami MO. Characterisation of human TDRD12 and LKAAEAR1 as potential oncogenic cancer testis antigen genes with clinical potential. Bangor University (United Kingdom); 2019.
Aluganti Narasimhulu C, Singla DK (2020) The role of bone morphogenetic protein 7 (BMP-7) in inflammation in heart diseases. Cells 9(2):280. https://doi.org/10.3390/cells9020280
American Diabetes Association (2010) Diagnosis and classification of diabetes mellitus. Diabetes Care 33(Supplement 1):S62–S69. https://doi.org/10.2337/dc10-S062
Bai Y, Wang J, He Z, Yang M, Li L, Jiang H (2019) Mesenchymal stem cells reverse diabetic nephropathy disease via lipoxin A4 by targeting transforming growth factor β (TGF-β)/smad pathway and pro-Inflammatory cytokines. Medical Science Monitor: International Medical Journal of Experimental and Clinical Research 25:3069. https://doi.org/10.12659/MSM.914860
Ballatori N, Krance SM, Notenboom S, Shi S, Tieu K, Hammond CL (2009) Glutathione dysregulation and the etiology and progression of human diseases. Biol Chem 390(3):191–214. https://doi.org/10.1515/BC.2009.033
Behl T, Kaur I, Kotwani A (2016) Implication of oxidative stress in progression of diabetic retinopathy. Surv Ophthalmol 61(2):187–196. https://doi.org/10.1016/j.survophthal.2015.06.001
Bell K, Teister J, Grus F (2018) Modulation of the immune system for the treatment of glaucoma. Curr Neuropharmacol 16(7):942–958. https://doi.org/10.2174/1570159X15666170720094529
Bonfiglio V, Platania CB, Lazzara F, Conti F, Pizzo C, Reibaldi M, Russo A, Fallico M, Ortisi E, Pignatelli F, Longo A (2020) TGF-β serum levels in diabetic retinopathy patients and the role of anti-VEGF therapy. Int J Mol Sci 21(24):9558. https://doi.org/10.3390/ijms21249558
Bosma EK, van Noorden CJ, Klaassen I, Schlingemann RO. Microvascular complications in the eye: diabetic retinopathy. InDiabetic Nephropathy 2019 (pp. 305–321). Springer, Cham. DOI: https://doi.org/10.4155/fmc.12.206
Boudina S, Abel ED (2010) Diabetic cardiomyopathy, causes and effects. Rev Endocr Metab Disord 11(1):31–39. https://doi.org/10.1007/s11154-010-9131-7
Centers for Disease Control and Prevention. National Diabetes Statistics Report (2020). Atlanta: Centers for Disease Control and Prevention, US Dept of Health and Human Services. 2020. https://www.cdc.gov/diabetes/data/statistics-report/index.html . Accessed on 12 April 2021
Chang AS, Hathaway CK, Smithies O, Kakoki M (2016) Transforming growth factor-β1 and diabetic nephropathy. American Journal of Physiology-Renal Physiology 310(8):F689–F696. https://doi.org/10.1152/ajprenal.00502.2015
Chaqour B, Karrasch C (2020) Eyeing the extracellular matrix in vascular development and microvascular diseases and bridging the divide between vascular mechanics and function. Int J Mol Sci 21(10):3487. https://doi.org/10.3390/ijms21103487
Cromer WE, Mathis JM, Granger DN, Chaitanya GV, Alexander JS (2011) Role of the endothelium in inflammatory bowel diseases. World J Gastroenterol: WJG 17(5):578. https://doi.org/10.3748/wjg.v17.i5.578
Das A, Henderson FC, Alshareef M, Porto GB, Kanginakudru I, Infinger LK, Vandergrift WA, Lindhorst SM, Varma AK, Patel SJ, Cachia D (2020) MGMT-inhibitor in combination with TGF-βRI inhibitor or CDK 4/6 inhibitor increases temozolomide sensitivity in temozolomide-resistant glioblastoma cells. Clin Transl Oncol 25:1–8. https://doi.org/10.1007/s12094-020-02456-x
Delgado-Tirado S, Amarnani D, Zhao G, Rossin EJ, Eliott D, Miller JB, Greene WA, Ramos L, Arevalo-Alquichire S, Leyton-Cifuentes D, Gonzalez-Buendia L (2020) Topical delivery of a small molecule RUNX1 transcription factor inhibitor for the treatment of proliferative vitreoretinopathy. Sci Rep 10(1):1–5. https://doi.org/10.1038/s41598-020-77254-0
Devocelle A, Lecru L, François H, Desterke C, Gallerne C, Eid P, Estelle O, Azzarone B, Giron-Michel J (2019) Inhibition of TGF-β1 signaling by IL-15: a novel role for IL-15 in the control of renal epithelial-mesenchymal transition: IL-15 counteracts TGF-β1-induced EMT in renal fibrosis. International Journal of Cell Biology 7:2019. https://doi.org/10.1155/2019/9151394
Dodagatta-Marri E, Meyer DS, Reeves MQ, Paniagua R, To MD, Binnewies M, Broz ML, Mori H, Wu D, Adoumie M, Del Rosario R (2019) α-PD-1 therapy elevates Treg/Th balance and increases tumor cell pSmad3 that are both targeted by α-TGFβ antibody to promote durable rejection and immunity in squamous cell carcinomas. J Immunother Cancer 7(1):1–5. https://doi.org/10.1186/s40425-018-0493-9
Estrada LD, Oliveira-Cruz L, Cabrera D (2018) Transforming growth factor beta type I role in neurodegeneration: implications for Alzheimer s disease. Curr Protein Pept Sci 19(12):1180–1188. https://doi.org/10.2174/1389203719666171129094937
Formenti SC, Lee P, Adams S, Goldberg JD, Li X, **e MW, Ratikan JA, Felix C, Hwang L, Faull KF, Sayre JW (2018) Focal irradiation and systemic TGFβ blockade in metastatic breast cancer. Clin Cancer Res 24(11):2493–2504. https://doi.org/10.1158/1078-0432.CCR-17-3322
François H, Chatziantoniou C (2018) Renal fibrosis: recent translational aspects. Matrix Biol 1(68):318–332. https://doi.org/10.1016/j.matbio.2017.12.013
Giacco F, Brownlee M (2010) Oxidative stress and diabetic complications. Circ Res 107(9):1058–1070. https://doi.org/10.1161/CIRCRESAHA.110.223545
Gonzalez-Junca A, Reiners O, Borrero-Garcia LD, Beckford-Vera D, Lazar AA, Chou W, Braunstein S, VanBrocklin H, Franc BL, Barcellos-Hoff MH (2021) Positron emission tomography imaging of functional TGFβ activity and benefit of TGFβ Inhibition in irradiated intracranial tumors. Int J Radiat Oncol Biol Phys 109(2):527. https://doi.org/10.1016/j.ijrobp.2020.09.043
Goumans MJ, Ten Dijke P (2018) TGF-β signaling in control of cardiovascular function. Cold Spring Harb Perspect Biol 10(2):a022210. https://doi.org/10.1101/cshperspect.a022210
Gu YY, Liu XS, Huang XR, Yu XQ, Lan HY (2020) Diverse role of TGF-β in kidney disease. Frontiers in Cell and Developmental Biology 28(8):123. https://doi.org/10.3389/fcell.2020.00123
Gupta A, Behl T, Panichayupakaranan P (2019) A review of phytochemistry and pharmacology profile of Juglans regia. Obesity Medicine 1(16):100142. https://doi.org/10.1016/j.obmed.2019.100142
Gupta A, Behl T, Sachdeva M. Key milestones in the diabetes research: a comprehensive update. Obesity Medicine. 2020:100183. https://doi.org/10.1016/j.obmed.2020.100183
Gupta A, Behl T, Sehgal A, Bhardwaj S, Singh S, Sharma N, Hafeez A (2021a) Exploring the recent molecular targets for diabetes and associated complications. Mol Biol Rep 24:1–7. https://doi.org/10.1007/s11033-021-06294-0
Gupta A, Behl T, Sehgal A, Bhatia S, Jaglan D, Bungau S (2021b) Therapeutic potential of Nrf-2 pathway in the treatment of diabetic neuropathy and nephropathy. Molecular Biology Reports. 2021b Mar 22:1–4.):581–9. https://doi.org/10.1007/s11033-021-06257-5
Guzman DC, Olguín HJ, García EH, Peraza AV, de la Cruz DZ, Soto MP (2017) Mechanisms involved in the development of diabetic retinopathy induced by oxidative stress. Redox Rep 22(1):10–16. https://doi.org/10.1080/13510002.2016.1205303
Hewitson TD, Holt SG, Tan SJ, Wigg B, Samuel CS, Smith ER (2017) Epigenetic modifications to H3K9 in renal tubulointerstitial cells after unilateral ureteric obstruction and TGF-β1 stimulation. Front Pharmacol 29(8):307. https://doi.org/10.3389/fphar.2017.00307
Hills CE, Squires PE (2011) The role of TGF-β and epithelial-to mesenchymal transition in diabetic nephropathy. Cytokine Growth Factor Rev 22(3):131–139. https://doi.org/10.1016/j.cytogfr.2011.06.002
IDF data (https://diabetesatlas.org/data/en/world/). Accessed on 22-August-2020
Keedy VL, Bauer TM, Clarke JM, Hurwitz H, Baek I, Ha I, Ock CY, Nam SY, Kim M, Park N, Kim JY. Association of TGF-β responsive signature with anti-tumor effect of vactosertib, a potent, oral TGF-β receptor type I (TGFBRI) inhibitor in patients with advanced solid tumors. https://doi.org/10.1200/JCO.2018.36.15_SUPPL.3031
Kim KS, Park JM, Kong T, Kim C, Bae SH, Kim HW, Moon J (2016) Retinal angiogenesis effects of TGF-β1 and paracrine factors secreted from human placental stem cells in response to a pathological environment. Cell Transplant 25(6):1145–1157. https://doi.org/10.3727/096368915X688263
Latha M, Pari L, Ramkumar KM, Rajaguru P, Suresh T, Dhanabal T, Sitasawad S, Bhonde R (2009) Antidiabetic effects of scoparic acid D isolated from Scoparia dulcis in rats with streptozotocin-induced diabetes. Nat Prod Res 23(16):1528–1540. https://doi.org/10.1080/14786410902726126
Li JH, Huang XR, Zhu HJ, Johnson R, Lan HY (2003) Role of TGF-β signaling in extracellular matrix production under high glucose conditions. Kidney Int 63(6):2010–2019. https://doi.org/10.1046/j.1523-1755.2003.00016.x
Li Q, Pang L, Yang W, Liu X, Su G, Dong Y (2018) Long non-coding RNA of myocardial infarction associated transcript (LncRNA-MIAT) promotes diabetic retinopathy by upregulating transforming growth factor-β1 (TGF-β1) signaling. Medical Science Monitor: International Medical Journal of Experimental and Clinical Research 24:9497. https://doi.org/10.12659/MSM.911787
Liguori GR, Liguori TT, de Moraes SR, Sinkunas V, Terlizzi V, van Dongen JA, Sharma PK, Moreira LF, Harmsen MC. Molecular and biomechanical clues from cardiac tissue decellularized extracellular matrix drive stromal cell plasticity. Frontiers in bioengineering and biotechnology. 2020;8. https://doi.org/10.3389/fbioe.2020.00520
Liu F, Zhuang S. New therapies for the treatment of renal fibrosis. Renal Fibrosis: Mechanisms and Therapies. 2019:625–59. https://doi.org/10.1007/978-981-13-8871-2_31
Liu G, Ma C, Yang H, Zhang PY (2017) Transforming growth factor β and its role in heart disease. Exp Ther Med 13(5):2123–2128. https://doi.org/10.3892/etm.2017.4246
López-Hernández FJ, López-Novoa JM (2012) Role of TGF-β in chronic kidney disease: an integration of tubular, glomerular and vascular effects. Cell Tissue Res 347(1):141–154. https://doi.org/10.1007/s00441-011-1275-6
Luis-Rodríguez D, Martínez-Castelao A, Górriz JL, De-Álvaro F, Navarro-González JF (2012) Pathophysiological role and therapeutic implications of inflammation in diabetic nephropathy. World J Diabetes 3(1):7. https://doi.org/10.4239/wjd.v3.i1.7
Meng XM, Tang PM, Li J, Lan HY (2015) TGF-β/Smad signaling in renal fibrosis. Front Physiol 19(6):82. https://doi.org/10.3389/fphys.2015.00082
Nadarajah R, Milagres R, Dilauro M, Gutsol A, **ao F, Zimpelmann J, Kennedy C, Wysocki J, Batlle D, Burns KD (2012) Podocyte-specific overexpression of human angiotensin-converting enzyme 2 attenuates diabetic nephropathy in mice. Kidney Int 82(3):292–303. https://doi.org/10.1038/ki.2012.83
Niwa T, Yamakoshi Y, Yamazaki H, Karakida T, Chiba R, Hu JC, Nagano T, Yamamoto R, Simmer JP, Margolis HC, Gomi K (2018) The dynamics of TGF-β in dental pulp, odontoblasts and dentin. Sci Rep 8(1):1–4. https://doi.org/10.1038/s41598-018-22823-7
Papachristodoulou A, Silginer M, Weller M, Schneider H, Hasenbach K, Janicot M, Roth P (2019) Therapeutic targeting of tgfβ ligands in glioblastoma using novel antisense oligonucleotides reduces the growth of experimental gliomas. Clin Cancer Res 25(23):7189–7201. https://doi.org/10.1158/1078-0432.CCR-17-3024
Parim B, Uddandrao VS, Saravanan G (2019) Diabetic cardiomyopathy: molecular mechanisms, detrimental effects of conventional treatment, and beneficial effects of natural therapy. Heart Fail Rev 24(2):279–299. https://doi.org/10.1007/s10741-018-9749-1
Patel RK, Prasad N, Kuwar R, Haldar D, Abdul-Muneer PM (2017) Transforming growth factor-beta 1 signaling regulates neuroinflammation and apoptosis in mild traumatic brain injury. Brain Behav Immun 1(64):244–258. https://doi.org/10.1016/j.bbi.2017.04.012
Ramkumar KM, Vijayakumar RS, Vanitha P, Suganya N, Manjula C, Rajaguru P, Sivasubramanian S, Gunasekaran P (2014) Protective effect of gallic acid on alloxan-induced oxidative stress and osmotic fragility in rats. Hum Exp Toxicol 33(6):638–649. https://doi.org/10.1177/0960327113504792
Rana D, Kumar A (2019) Is there a role for sodium orthovanadate in the treatment of diabetes? Curr Diabetes Rev 15(4):284–287. https://doi.org/10.2174/1573399814666180903162556
Reeves WB, Andreoli TE (2000) Transforming growth factor β contributes to progressive diabetic nephropathy. Proc Natl Acad Sci 97(14):7667–7669. https://doi.org/10.1073/pnas.97.14.7667
Reiss KA, Ben-Josef E, Damjanov N, Hoteit M, Karasic TB, Carpenter E, DiCicco L, Garcia-Marcano LA, Mick R, Vonderheide RH. A pilot study of galunisertib (LY2157299 monohydrate) plus stereotactic body radiotherapy (SBRT) in advanced hepatocellular carcinoma (HCC). https://doi.org/10.1200/JCO.2019.37.4_suppl.270
Ruiz-Ortega M, Rayego-Mateos S, Lamas S, Ortiz A, Rodrigues-Diez RR (2020) Targeting the progression of chronic kidney disease. Nat Rev Nephrol 16(5):269–288. https://doi.org/10.1038/s41581-019-0248-y
Russo LM, del Re E, Brown D, Lin HY (2007) Evidence for a role of transforming growth factor (TGF)-β1 in the induction of postglomerular albuminuria in diabetic nephropathy: amelioration by soluble TGF-β type II receptor. Diabetes 56(2):380–388. https://doi.org/10.2337/db06-1018
Sabaner MC, Akdogan M, Doğan M, Oral AY, Duman R, Koca T, Bozkurt E (2020) Inflammatory cytokines, oxidative and antioxidative stress levels in patients with diabetic macular edema and hyperreflective spots. Eur J Ophthalmol 2:1120672120962054. https://doi.org/10.1177/1120672120962054
Schrementi ME, Ferreira AM, Zender C, DiPietro LA (2008) Site-specific production of TGF-β in oral mucosal and cutaneous wounds. Wound Repair and Regeneration 16(1):80–86. https://doi.org/10.1111/j.1524-475X.2007.00320.x
Sharma S, Behl T, Kumar A, Sehgal A, Singh S, Sharma N, Bhatia S, Al-Harrasi A, Bungau S (2021) Targeting endothelin in Alzheimer’s disease: A Promising Therapeutic Approach. Biomed Res Int 7:2021. https://doi.org/10.1155/2021/7396580
Shi GJ, Shi GR, Zhou JY, Zhang WJ, Gao CY, Jiang YP, Zi ZG, Zhao HH, Yang Y, Yu JQ (2018) Involvement of growth factors in diabetes mellitus and its complications: a general review. Biomed Pharmacother 1(101):510–527. https://doi.org/10.1016/j.biopha.2018.02.105
Shikatani EA, Husain M. The role of growth differentiation factor 5 in cardiac repair post-myocardial infarction. In Cardiac Remodeling 2013 (pp. 365–382). Springer, New York, NY. DOI: https://doi.org/10.1007/978-1-4614-5930-9_21
Siwecka N, Rozpędek W, Pytel D, Wawrzynkiewicz A, Dziki A, Dziki Ł, Diehl JA, Majsterek I (2019) Dual role of endoplasmic reticulum stress-mediated unfolded protein response signaling pathway in carcinogenesis. Int J Mol Sci 20(18):4354. https://doi.org/10.3390/ijms20184354
Song KM, Choi MJ, Ghatak K, Minh NN, Kwon MH, Ock J, Yin GN, Ryu JK, Suh JK. AB083. TEW-7197, a novel orally bioavailable activin receptor-like kinase 5 inhibitor, promotes regression of fibrotic plaque in a rat model of Peyronie’s disease. Translational Andrology and Urology. 2018 Sep;7(Suppl 5). DOI: https://doi.org/10.21037/tau.2018.AB083
Strauss J, Heery CR, Schlom J, Madan RA, Cao L, Kang Z, Lam** E, Marté JL, Donahue RN, Grenga I, Cordes L (2018) Phase I trial of M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGFβ, in advanced solid tumors. Clin Cancer Res 24(6):1287–1295. https://doi.org/10.1158/1078-0432.CCR-17-2653
Sulli G, Lam MT, Panda S (2019) Interplay between circadian clock and cancer: new frontiers for cancer treatment. Trends in Cancer 5(8):475–494. https://doi.org/10.1016/j.trecan.2019.07.002
Sutariya B, Jhonsa D, Saraf MN (2016) TGF-β: the connecting link between nephropathy and fibrosis. Immunopharmacol Immunotoxicol 38(1):39–49. https://doi.org/10.3109/08923973.2015.1127382
Taher MA, Dawood DH, Sanad MI, Hassan RA (2016) Searching for anti-hyperglycemic phytomolecules of Tecoma stans. Eur J Chem 7(4):397–404. https://doi.org/10.5155/eurjchem.7.4.397-404.1478
Takir M, Unal AD, Kostek O, Bayraktar N, Demirag NG. Cystatin-C and TGF-β levels in patients with diabetic nephropathy. nefrologia. 2016 Nov 1;36(6):653–9. https://doi.org/10.1016/j.nefro.2016.06.011
Tarbit E, Singh I, Peart JN, Rose’Meyer RB. Biomarkers for the identification of cardiac fibroblast and myofibroblast cells. Heart failure reviews. 2019 Jan 1;24(1):1–5. https://doi.org/10.1007/s10741-018-9720-1
Teixeira AF, Ten Dijke P, Zhu HJ. On-target anti-TGF-β therapies are not succeeding in clinical cancer treatments: what are remaining challenges?. Frontiers in cell and developmental biology. 2020;8. https://doi.org/10.3389/fcell.2020.00605
Theron AJ, Anderson R, Rossouw TM, Steel HC (2017) The role of transforming growth factor beta-1 in the progression of HIV/AIDS and development of non-AIDS-defining fibrotic disorders. Front Immunol 2(8):1461. https://doi.org/10.3389/fimmu.2017.01461
Tijsen AJ, Van Der Made I, van den Hoogenhof MM, Wijnen WJ, van Deel ED, De Groot NE, Alekseev S, Fluiter K, Schroen B, Goumans MJ, van der Velden J (2014) The microRNA-15 family inhibits the TGFβ-pathway in the heart. Cardiovasc Res 104(1):61–71. https://doi.org/10.1093/cvr/cvu184
Vallon V, Thomson SC (2020) The tubular hypothesis of nephron filtration and diabetic kidney disease. Nat Rev Nephrol 16(6):317–336. https://doi.org/10.1038/s41581-020-0256-y
Vallon V (2020) Glucose transporters in the kidney in health and disease. Pflügers Archiv-European Journal of Physiology 6:1–26. https://doi.org/10.1007/s00424-020-02361-w
Vega G, Alarcón S, San MR (2016) The cellular and signalling alterations conducted by TGF-β contributing to renal fibrosis. Cytokine 1(88):115–125. https://doi.org/10.1016/j.cyto.2016.08.019
Wang W, Lo AC (2018) Diabetic retinopathy: pathophysiology and treatments. Int J Mol Sci 19(6):1816. https://doi.org/10.1152/ajprenal.00502.2015
Wosikowski K, Korbmacher B, Krampert M, Roehl I, Janicot M. Extended preclinical ocular biodistribution and pharmacodynamic profile of ISTH0036, an antisense oligonucleotide targeting transforming growth factor beta 2 (TGF-β2) for the treatment of ophthalmic diseases. humor. 2018 Jul 1;100:0.
Yokoyama H, Deckert T (1996) Central role of TGF-β in the pathogenesis of diabetic nephropathy and macrovascular complications: a hypothesis. Diabet Med 13(4):313–320. https://doi.org/10.1002/(SICI)1096-9136(199604)13:4%3c313::AID-DIA56%3e3.0.CO;2-7
Yoshiji H, Kuriyama S, Kawata M, Yoshii J, Ikenaka Y, Noguchi R, Nakatani T, Tsu**oue H, Fukui H (2001) The angiotensin-I-converting enzyme inhibitor perindopril suppresses tumor growth and angiogenesis: possible role of the vascular endothelial growth factor. Clin Cancer Res 7(4):1073–1078. https://doi.org/10.1159/000069792
Zhang D, Qin H, Leng Y, Li X, Zhang L, Bai D, Meng Y, Wang J (2018) LncRNA MEG3 overexpression inhibits the development of diabetic retinopathy by regulating TGF-β1 and VEGF. Exp Ther Med 16(3):2337–2342. https://doi.org/10.3892/etm.2018.6451
Zhang H, Hu J, Liu L (2017) MiR-200a modulates TGF-β1-induced endothelial-to-mesenchymal shift via suppression of GRB2 in HAECs. Biomed Pharmacother 1(95):215–222. https://doi.org/10.1016/j.biopha.2017.07.104
Zhu J, Fu W, Jia W, **a H, Liu GC, He J (2018) Association between NER pathway gene polymorphisms and Wilms tumor risk. Molecular Therapy-Nucleic Acids 7(12):854–860. https://doi.org/10.1016/j.omtn.2018.08.002
Zipes DP, Libby P, Bonow RO, Mann DL, Tomaselli GF. Braunwald's heart disease e-book: a textbook of cardiovascular medicine. Elsevier Health Sciences; 2018 Jan 9
Author information
Authors and Affiliations
Contributions
Conceptualization, TB and AG; writing—original draft preparation, AG and TB; figure making, AS, SS, and NS; writing—review and editing, MG, SB, and SBU; proofreading, AAH and LA.
Corresponding author
Ethics declarations
Ethics approval
Not applicable.
Consent to participate
Not applicable.
Consent for publication
All the authors have approved the manuscript for publication.
Competing interests
The authors declare no competing interests.
Additional information
Responsible Editor: Philippe Garrigues
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Behl, T., Gupta, A., Sehgal, A. et al. Exploring the multifaceted role of TGF-β signaling in diabetic complications. Environ Sci Pollut Res 29, 35643–35656 (2022). https://doi.org/10.1007/s11356-022-19499-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11356-022-19499-y